Arcellx, Inc. (ACLX) Makes Progress on Multiple Myeloma Treatment

Group 1 - Arcellx Inc. (NASDAQ:ACLX) is recognized by Wall Street analysts as a promising biotech stock, particularly following the positive results from the Pivotal Phase 2 study of anitocabtagene autoleucel (anito-cel) for patients with relapsed or refractory multiple myeloma [1][2] - The iMMagine-1 study demonstrated deep and durable responses with a predictable and manageable safety profile, with no observed adverse effects such as Parkinsonism or Guillain-Barré syndrome [2] - Dr. Krina Patel highlighted the significance of the trial data as an important advancement for patients with multiple myeloma [3] Group 2 - Stifel has maintained a Buy rating on Arcellx, setting a price target of $127, citing impressive initial data from the Phase 3 MajesTEC-3 trial, which showed landmark progression-free survival and overall survival rates [4] - Arcellx is a clinical-stage biotech company focused on developing innovative cell therapies for cancer and autoimmune diseases, utilizing proprietary D-Domain technology (ddCAR) and the ARC-SparX platform [5]